Beta3-adrenoceptor agonists: Possible role in the treatment of overactive bladder

Korean Journal of Urology

Volumn 51, Issue 12, 2010, Pages 811-818

  Igawa, Yasuhiko ^a   Aizawa, Naoki ^a   Homma, Yukio ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Adrenergic beta agonists; Afferent pathways; Overactive; Urinary bladder

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; 4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; 5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; 5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY]PROPYL]AMINO]ETHOXY]SALICYLAMIDE; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUPRANOLOL; CATECHOLAMINE; DOBUTAMINE; ISOPRENALINE; MESSENGER RNA; MIRABEGRON; NITRIC OXIDE; PLACEBO; PROCATEROL; RECEPTOR SUBTYPE; SOLABEGRON; TOLTERODINE;

ADRENERGIC STIMULATION; BLADDER CAPACITY; CHROMOSOME 8; CONSTIPATION; DETRUSOR MUSCLE; DRUG EFFICACY; DRUG POTENCY; DYSPEPSIA; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MICTURITION; NAUSEA; NONHUMAN; OVERACTIVE BLADDER; PALMITOYLATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN STRUCTURE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SMOOTH MUSCLE RELAXATION; URINE RETENTION; UROTHELIUM; XEROSTOMIA;

EID: 78650897515     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2010.51.12.811     Document Type: Review

References (48)

1. Lands AM, Arnold A, McAuliff JP, Luduena FP, Brown TG Jr. Differentiation of receptor systems activated by sympathomimetic amines. Nature 1967;214:597-8.
2. Ursino MG, Vasina V, Raschi E, Crema F, De Ponti F. The beta3-adrenoceptor as a therapeutic target: current perspectives. Pharmacol Res 2009;59:221-34.
3. Emorine LJ, Marullo S, Briend-Sutren MM, Patey G, Tate K, Delavier-Klutchko C, et al. Molecular characterization of the human beta 3-adrenergic receptor. Science 1989; 245:1118-21. (Pubitemid 19231821)
4. Nergardh A, Boreus LO, Naglo AS. Characterization of the adrenergic beta-receptor in the urinary bladder of man and cat. Acta Pharmacol Toxicol 1977;40:14-21. (Pubitemid 8015345)
5. Larsen JJ. Alpha and beta-adrenoceptors in the detrusor muscle and bladder base of the pig and beta-adrenoceptors in the detrusor muscle of man. Br J Pharmacol 1979;65:215-22.
6. Morita T, Iizuka H, Iwata T, Kondo S. Function and distribution of beta3-adrenoceptors in rat, rabbit and human urinary bladder and external urethral sphincter. J Smooth Muscle Res 2000;36:21-32. (Pubitemid 30365869)
7. Oshita M, Hiraoka Y, Watanabe Y. Characterization of beta-adrenoceptors in urinary bladder: comparison between rat and rabbit. Br J Pharmacol 1997;122:1720-4. (Pubitemid 28000200)
8. Yamazaki Y, Takeda H, Akahane M, Igawa Y, Nishizawa O, Ajisawa Y. Species differences in the distribution of beta-adrenoceptor subtypes in bladder smooth muscle. Br J Pharmacol 1998;124:593-9.
9. Longhurst PA, Levendusky M. Pharmacological characterization of beta-adrenoceptors mediating relaxation of the rat urinary bladder in vitro. Br J Pharmacol 1999;127:1744-50.
10. Takeda H, Matsuzawa A, Igawa Y, Yamazaki Y, Kaidoh K, Akahane S, et al. Functional characterization of beta-adrenoceptor subtypes in the canine and rat lower urinary tract. J Urol 2003;170:654-8.
11. Yamanishi T, Chapple CR, Yasuda K, Yoshida K, Chess-Williams R. The role of beta(3)-adrenoceptors in mediating relaxation of porcine detrusor muscle. Br J Pharmacol 2002;135:129-34.
12. Strosberg AD. Structure and function of the beta 3-adrenergic receptor. Annu Rev Pharmacol Toxicol 1997;37:421-50.
13. Strosberg AD, Pietri-Rouxel F. Function and regulation of the beta 3-adrenoceptor. Trends Pharmacol Sci 1996;17:373-81.
14. Igawa Y, Yamazaki Y, Takeda H, Hayakawa K, Akahane M, Ajisawa Y, et al. Functional and molecular biological evidence for a possible beta3-adrenoceptor in the human detrusor muscle. Br J Pharmacol 1999;126:819-25. (Pubitemid 29087864)
15. Fujimura K, Tamura K, Tsutsumi T, Yamamoto T, Nakamura K, Koibuchi Y, et al. Expression and possible functional role of the beta3-adrenoceptor in human and rat detrusor muscle. J Urol 1999;161:680-5.
16. Takeda M, Obara K, Mizusawa T, Tomita Y, Arai K, Tsutsui T, et al. Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J Pharmacol Exp Ther 1999;288:1367-73.
17. Nomiya M, Yamaguchi O. A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol 2003;170:649-53.
18. Yamaguchi O, Chapple CR. Beta3-adrenoceptors in urinary bladder. Neurourol Urodyn 2007;26:752-6.
19. Michel MC, Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 2006;147(Suppl 2):S88-119.
20. Vrydag W, Michel MC. Tools to study beta3-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 2007;374:385-98.
21. Igawa Y, Yamazaki Y, Takeda H, Akahane M, Ajisawa Y, Yoneyama T, et al. Possible beta 3-adrenoceptor- mediated relaxation of the human detrusor. Acta Physiol Scand 1998;164:117-8.
22. Igawa Y, Yamazaki Y, Takeda H, Kaidoh K, Akahane M, Ajisawa Y, et al. Relaxant effects of isoproterenol and selective beta3-adrenoceptor agonists on normal, low compliant and hyperreflexic human bladders. J Urol 2001;165:240-4.
23. Takeda H, Yamazaki Y, Akahane M, Igawa Y, Ajisawa Y, Nishizawa O. Role of the beta(3)-adrenoceptor in urine storage in the rat: comparison between the selective beta(3)-adrenoceptor agonist, CL316, 243,and various smooth muscle relaxants. J Pharmacol Exp Ther 2000;293:939-45.
24. Kaidoh K, Igawa Y, Takeda H, Yamazaki Y, Akahane S, Miyata H, et al. Effects of selective beta2 and beta3-adrenoceptor agonists on detrusor hyperreflexia in conscious cerebral infarcted rats. J Urol 2002;168:1247-52.
25. Woods M, Carson N, Norton NW, Sheldon JH, Argentieri TM. Efficacy of the beta3-adrenergic receptor agonist CL-316243 on experimental bladder hyperreflexia and detrusor instability in the rat. J Urol 2001;166:1142-7. (Pubitemid 32751059)
26. Takeda H, Yamazaki Y, Igawa Y, Kaidoh K, Akahane S, Miyata H, et al. Effects of beta(3)-adrenoceptor stimulation on prostaglandin E(2)-induced bladder hyperactivity and on the cardiovascular system in conscious rats. Neurourol Urodyn 2002;21:558-65.
27. Leon LA, Hoffman BE, Gardner SD, Laping NJ, Evans C, Lashinger ES, et al. Effects of the beta 3-adrenergic receptor agonist disodium 5-[(2R)-2-[[(2R)-2- (3-chlorophenyl)-2-hydroxyethyl]amino] propyl]-1,3-benzodioxole-2,2- dicarboxylate (CL-316243) on bladder micturition reflex in spontaneously hypertensive rats. J Pharmacol Exp Ther 2008;326:178-85.
28. Igawa Y. Discussion: functional role of M(1), M(2), and M(3) muscarinic receptors in overactive bladder. Urology 2000;55(5A Suppl):47-9.
29. Ehlert FJ, Ahn S, Pak KJ, Park GJ, Sangnil MS, Tran JA, et al. Neuronally released acetylcholine acts on the M2 muscarinic receptor to oppose the relaxant effect of isoproterenol on cholinergic contractions in mouse urinary bladder. J Pharmacol Exp Ther 2007;322:631-7.
30. Takasu T, Ukai M, Sato S, Matsui T, Nagase I, Maruyama T, et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl) amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 2007;321:642-7.
31. Uchida H, Shishido K, Nomiya M, Yamaguchi O. Involvement of cyclic AMP-dependent and -independent mechanisms in the relaxation of rat detrusor muscle via beta-adrenoceptors. Eur J Pharmacol 2005;518:195-202.
32. Frazier EP, Mathy MJ, Peters SL, Michel MC. Does cyclic AMP mediate rat urinary bladder relaxation by isoproterenol? J Pharmacol Exp Ther 2005;313:260-7.
33. Otsuka A, Shinbo H, Matsumoto R, Kurita Y, Ozono S. Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium. Naunyn Schmiedebergs Arch Pharmacol 2008;377:473-81.
34. Birder LA, Nealen ML, Kiss S, de Groat WC, Caterina MJ, Wang E, et al. Beta -adrenoceptor agonists stimulate endothelial nitric oxide synthase in rat urinary bladder urothelial cells. J Neurosci 2002;22:8063-70.
35. Murakami S, Chapple CR, Akino H, Sellers DJ, Chess-Williams R. The role of the urothelium in mediating bladder responses to isoprenaline. BJU Int 2007;99:669-73.
36. Masunaga K, Chapple CR, McKay NG, Yoshida M, Sellers DJ. The β3-adrenoceptor mediates the inhibitory effects of β-adrenoceptor agonists via the urothelium in pig bladder dome. Neurourol Urodyn 2010;29:1320-5.
37. Otsuka A, Matsumoto R, Shinbo H, Imanishi T, Kurita Y, Ozono S. Distribution of beta-adrenoceptor subtypes in suburothelial interstitial cells in the human urinary bladder. Nueouro Urodyn 2009;28(Suppl):871-2, abstract 225.
38. Limberg BJ, Andersson KE, Aura Kullmann F, Burmer G, de Groat WC, Rosenbaum JS. β-adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female bladder. Cell Tissue Res 2010;342:295-306.
39. Aizawa N, Igawa Y, Nishizawa O, Wyndaele JJ. Effects of CL316,243, a beta 3-adrenoceptor agonist, and intravesical prostaglandin E2 on the primary bladder afferent activity of the rat. Neurourol Urodyn 2010;29:771-6.
40. Arch JR, Ainsworth AT, Cawthorne MA, Piercy V, Sennitt MV, Thody VE, et al. Atypical beta-adrenoceptor on brown adipocytes as a target for anti-obesity drugs. Nature 1984;309:163-5.
41. Dolan JA, Muenkel HA, Burns MG, Pellegrino SM, Fraser CM, Pietri F, et al. Beta-3 adrenoceptor selectivity of the dioxolane dicarboxylate phenethanolamines. J Pharmacol Exp Ther 1994;269:1000-6.
42. Michel MC, Ochodnicky P, Summers RJ. Tissue functions mediated by beta(3)-adrenoceptors-findings and challenges. Naunyn Schmiedebergs Arch Pharmacol 2010;382:103-8.
43. Hu B, Jennings LL. Orally bioavailable beta 3-adrenergic receptor agonists as potential therapeutic agents for obesity and type-II diabetes. Prog Med Chem 2003;41:167-94.
44. Hicks A, McCafferty GP, Riedel E, Aiyar N, Pullen M, Evans C, et al. GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog. J Pharmacol Exp Ther 2007;323:202-9.
45. Biers SM, Reynard JM, Brading AF. The effects of a new selective beta3-adrenoceptor agonist (GW427353) on spontaneous activity and detrusor relaxation in human bladder. BJU Int 2006;98:1310-4.
46. www.clinicaltrials.gov
47. Chapple CR, Yamaguchi O, Ridder A, Liehne J, Carl S, Mattiasson A, et al. Clinical proof of concept study (Blossom) shows novel β3 adrenoceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder. Eur Urol 2008;(Suppl 7):239.
48. Chapple C, Wyndaele JJ, van Kerrebroeck P, Radziszewski P, Dvorak V, Boerrigter P. Dose-ranging study of once-daily mirabegron (YM178), a novel selective β3-adrenoceptor agonist, in patients with overactive bladder (OAB). Eur Urol 2010;(Suppl 9):249.